Revvity Reports Mixed Q1 2026 Results, Plans China Immunodiagnostics Divestiture
Event summary
- Revvity reported Q1 2026 revenue of $711 million, up 7% YoY, with GAAP EPS of $0.37.
- Adjusted operating profit margin declined to 23.6% from 25.6% YoY.
- The company announced plans to divest its China Immunodiagnostics business, representing 6% of 2025 revenue.
- Pro forma Q1 2026 EPS was $0.40, compared to $(0.13) in the same period a year ago.
- Full-year 2026 revenue guidance is $2.81-$2.84 billion, with pro forma organic revenue growth of 3%-4%.
The big picture
Revvity's Q1 2026 results reflect a mixed performance with revenue growth offset by declining profit margins. The strategic decision to divest its China Immunodiagnostics business signals a shift in portfolio optimization, aiming to capitalize on improving market conditions. The company's ability to execute this divestiture and maintain growth will be critical in delivering differentiated results for shareholders.
What we're watching
- Divestiture Impact
- How the divestiture of the China Immunodiagnostics business will affect Revvity's revenue and operational focus.
- Market Conditions
- Whether Revvity can sustain its organic growth amid improving market conditions.
- Profitability Trends
- The pace at which Revvity can stabilize its adjusted operating profit margin.
Related topics